PropThink’s Weekly Healthcare Wrap-Up
- Pharmacyclics warned in its 3Q earnings release that employees might sell market-moving amounts of shares on Wednesday as they exercised options. As we expected, shares sold off sharply but bounced in the second half of the week.
- Remoxy has long been an interest for PropThink, and this week we focused on Durect’s involvement in the pain management drug. Pfizer’s comments were damaging, but opportunity still exists.
- The risk-tolerant investor will want to read our report on Geron, while those interested in a safer bet for 2013 should take a look at Endocyte .
- Pimavanserin remains a controversial issue among the Bulls and Bears. Here’s an evaluation of its potential should upcoming data prove positive for Acadia.
- PropThink’s discussion of AMED in mid-October suggested declines in the near-future, which continued post-earnings with analyst downgrades this week. Shares are off 17% since PropThink’s first story.
- Pending FDA approval, Ariad is fully prepared for ponatinib’s launch next year, and InterMune’s Esbriet sales have finally begun to show signs of life.
- Following our previous report on Biogen Idec, we opined this week on development data from the biotech giant. Once BG-12 receives approval, expect investor focus to shift to the pipeline, and here’s a good look at what’s coming.
- Amarin’s conference call didn’t shed a whole lot of light on Vascepa’s NCE status, but management did lend some insight on its plans for marketing the drug. We still think investors should tread lightly, utilizing options around this volatile event.
- Our original report on Merge Healthcare ran in September, and while the stock has been under pressure since October, Reuters reported on Friday that private equity firms have been circling the healthcare IT company, and fundamentals are solid.
- Keryx has a series of trial-related catalysts by the end of the year, which management reiterated in this week’s conference call. Spectrum Pharmaceuticals closed out the week flat after an earnings beat.
- With catalysts approaching, solid data and commercial opportunity suggest paying some attention to Trius Therapeutics.
- Palatin Technologies (PTN) saw some quick action this week when it released data for bremelanotide, but didn’t hold gains in the short-term. However, its valuation suggests upside.
- We took a look at Vivus’ and Arena’s third quarter results, and what they might mean for Orexigen. And on Friday, Celsion set some hard deadlines for releasing ThermoDox Phase III data.
- ENDP missed Consensus revenue estimates, but subsequent weakness presents a buying opportunity for multiple reasons.
Additional disclosure: PropThink is a team of editors, analysts, and writers. Use of PropThink's research is at your own risk. You should do your own research and due diligence before making any investment decision with respect to securities covered herein.You should assume that as of the publication date of any report or letter, PropThink, LLC and persons or entities with whom it has relation ships (collectively referred to as "PropThink") has a position in all stocks (and/or options of the stock) covered herein that is consistent with the position set forth in our research report. Following publication of any report or letter, PropThink intends to continue transacting in the securities covered herein, and we may be long, short, or neutral at any time hereafter regardless of our initial recommendation. To the best of our knowledge and belief, all information contained herein is accurate and reliable, and has been obtained from public sources we believe to be accurate and reliable, and not from company insiders or persons who have a relationship with company insiders. Our full disclaimer is available at this link.